Philips has received clearance from the FDA to sell the latest version of its radiology informatics platform. The 510(k) clearance for IntelliSpace Portal 9.0 positions Philips to start selling the product in the U.S. this month.
Amsterdam-based Philips has expanded the list of clinical applications for the latest version of the platform. New additions to the now 70-strong list of applications include features related to the diagnosis and monitoring of neurological conditions and cancer.
To support neurologists, Philips has added longitudinal brain imaging capabilities to the platform. This function uses images of the brain to assess disease progression over time. The expectation is that physicians monitoring patients suffering from neurodegenerative disorders such as stroke, Alzheimer’s disease and multiple sclerosis will benefit from the capabilities.
Philips worked with neuroradiologists including Mark van Buchem, M.D., Ph.D., on the development of the latest iteration of the platform. Van Buchem, a professor of neuroradiology at the Leiden University Medical Center, sees the platform helping radiologists.
"Analytics applications optimized for clinical decision support and longitudinal and quantified patient tracking are becoming increasingly important to radiologists. They can help visualize and quantify very subtle manifestations of disease and differences over time that may not be seen with the naked eye,” van Buchem said in a statement. “IntelliSpace Portal 9.0 integrates into our existing workflow and adds greatly to our patient care.”
Philips has also built out the cancer capabilities of the platform. The ninth version of the platform features quantitative European Association for the Study of the Liver capabilities. This tumor-tracking tool is intended to show how cells are responding to treatment. Philips has also added lung cancer assessment capabilities.